• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 4. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Dimethoxybenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Methoxybenzenes Dimethoxybenzenes

Introduction to 1-(azidomethyl)-3,5-dimethoxybenzene (CAS No. 712329-47-0)

1-(azidomethyl)-3,5-dimethoxybenzene, identified by its Chemical Abstracts Service (CAS) number 712329-47-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and synthetic biology. This compound, featuring a benzene ring substituted with methoxy and azidomethyl groups, exhibits unique chemical properties that make it a valuable intermediate in the synthesis of various bioactive molecules. The presence of both electron-donating methoxy groups and the highly reactive azidomethyl moiety imparts distinct reactivity, enabling its utility in diverse chemical transformations.

The structural features of 1-(azidomethyl)-3,5-dimethoxybenzene make it particularly interesting for medicinal chemists exploring novel therapeutic agents. The methoxy groups enhance the lipophilicity and metabolic stability of the molecule, while the azidomethyl group serves as a versatile handle for further functionalization. This balance of properties has positioned the compound as a key building block in the development of small-molecule drugs targeting various biological pathways.

In recent years, advances in drug discovery have highlighted the importance of heterocyclic compounds with multiple substituents for their ability to modulate biological targets effectively. 1-(azidomethyl)-3,5-dimethoxybenzene fits well within this paradigm, offering a scaffold that can be modified to produce compounds with enhanced pharmacological profiles. Its application in fragment-based drug design and library synthesis has been explored to identify lead compounds for treating neurological disorders, inflammation, and infectious diseases.

One of the most compelling aspects of 1-(azidomethyl)-3,5-dimethoxybenzene is its role in click chemistry applications. The azidomethyl group is particularly useful in copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), a powerful tool for constructing complex molecular architectures rapidly and efficiently. This reaction has been leveraged to create conjugates with therapeutic potential, including radiolabeled probes for diagnostic imaging and bioconjugates for targeted drug delivery systems.

Recent studies have demonstrated the utility of 1-(azidomethyl)-3,5-dimethoxybenzene in synthesizing inhibitors of enzymes implicated in cancer progression. By incorporating this compound into libraries of heterocyclic derivatives, researchers have identified molecules that disrupt key signaling pathways involved in tumor growth and metastasis. The methoxy substituents contribute to selective binding interactions with target proteins, while the azidomethyl group allows for post-synthetic modifications to optimize potency and selectivity.

The synthesis of 1-(azidomethyl)-3,5-dimethoxybenzene itself presents an intriguing challenge due to the need to handle both reactive methoxy and azido functional groups under controlled conditions. Modern synthetic methodologies have enabled efficient access to this intermediate through multi-step sequences that minimize side reactions and maximize yield. Techniques such as palladium-catalyzed cross-coupling reactions and directed ortho-metalation strategies have been employed to construct the desired framework with high precision.

The pharmacokinetic properties of derivatives derived from 1-(azidomethyl)-3,5-dimethoxybenzene have been extensively studied to ensure their suitability for clinical applications. Computational modeling has played a crucial role in predicting how structural modifications will influence absorption, distribution, metabolism, and excretion (ADME) profiles. This approach has allowed medicinal chemists to design analogs with improved bioavailability and reduced toxicity.

As research continues to uncover new biological targets and mechanisms underlying disease pathogenesis, the demand for versatile intermediates like 1-(azidomethyl)-3,5-dimethoxybenzene is expected to grow. Its ability to serve as a precursor for structurally diverse bioactive molecules makes it an indispensable tool in modern drug discovery pipelines. Collaborative efforts between synthetic chemists and biologists are likely to yield novel therapeutic agents based on this promising scaffold.

The future directions for research involving 1-(azidomethyl)-3,5-dimethoxybenzene may include exploring its potential in green chemistry initiatives. Developing sustainable synthetic routes that minimize waste and hazardous byproducts will be essential as industries strive toward environmentally responsible practices. Additionally, investigating its role in photopharmacology—where light-sensitive compounds are used to modulate biological processes—could open up new avenues for treating conditions resistant to conventional therapeutics.

In conclusion,1-(azidomethyl)-3,5-dimethoxybenzene (CAS No. 712329-47-0) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and broad applicability. Its integration into drug discovery programs has yielded promising leads for treating diverse diseases, while ongoing research continues to expand its utility across multiple disciplines. As our understanding of molecular interactions deepens,1-(azidomethyl)-3,5-dimethoxybenzene is poised to remain at the forefront of innovation in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)